Verification evidence is still being completed.
PDF / print export
Aurealis Therapeutics
Kuopio, Finland
- Verified lead
- Juha Yrjanheikki
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- Live-Biotherapeutic Products, Engineered Lactic-Acid Bacteria, and Diabetic Foot Ulcer Treatment
- Review cycle
- 24 April 2026
- Full address
- Microkatu 1, FI-70210 Kuopio, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Aurealis Therapeutics About page naming Juha Yrjanheikki as CEO and Co-founder.
- Editorial note
- Kuopio clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply, and Phase 1 clinical activity on AUP-16 for diabetic foot ulcers.
Live-Biotherapeutic Products, Engineered Lactic-Acid Bacteria, and Diabetic Foot Ulcer Treatment
Public CEO disclosure on company site, Business Kuopio success-story documentation, Phase 1 clinical activity
Kuopio clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply, and Phase 1 clinical activity on AUP-16 for diabetic foot ulcers.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Kuopio, Finland
Aurealis Therapeutics
Live-Biotherapeutic Products, Engineered Lactic-Acid Bacteria, and Diabetic Foot Ulcer Treatment · Clinical-stage live-biotherapeutic development
Kuopio clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply, and Phase 1 clinical activity on AUP-16 for diabetic foot ulcers.
- Lead
- Juha Yrjanheikki (verified ↗)
- Address
- Microkatu 1, FI-70210 Kuopio, Finland (source ↗)
- Compliance
- GMP
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage live-biotherapeutic development
- Capabilities
- Strain Engineering of Lactic-Acid Bacteria · Live-Biotherapeutic Process Development · Phase 1 Diabetic Foot Ulcer Program
- Founded
- 2010
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Juha Yrjanheikki
Chief Executive Officer and Co-Founder
Full addressMicrokatu 1, FI-70210 Kuopio, Finland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Kuopio Health member page listing Aurealis Therapeutics at Microkatu 1, Kuopio.
Open sourceClinical-stage live-biotherapeutic development
Kuopio, Finland. Live-Biotherapeutic Products, Engineered Lactic-Acid Bacteria, and Diabetic Foot Ulcer Treatment. Review completed on 24 Apr 2026.
Fimea, Swissmedic, and EMA for clinical oversight
Public CEO disclosure on company site, Business Kuopio success-story documentation, Phase 1 clinical activity
Live-Biotherapeutic Products, Engineered Lactic-Acid Bacteria, and Diabetic Foot Ulcer Treatment
Kuopio clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply, and Phase 1 clinical activity on AUP-16 for diabetic foot ulcers.
Editorial note
Aurealis Therapeutics is a Finland-Swiss clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply for LBP programs, and Phase 1 clinical activity for AUP-16.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Strain Engineering of Lactic-Acid Bacteria
Live-Biotherapeutic Process Development
Phase 1 Diabetic Foot Ulcer Program
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Strain engineering laboratories
LBP process development
Clinical trial operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Aurealis Therapeutics located?
- Aurealis Therapeutics operates from Microkatu 1, FI-70210 Kuopio, Finland, Kuopio, Finland.
- Who runs Aurealis Therapeutics?
- Aurealis Therapeutics is led by Juha Yrjanheikki, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does Aurealis Therapeutics do?
- Kuopio clinical-stage live-biotherapeutic biotech with named co-founder CEO, GMP clinical supply, and Phase 1 clinical activity on AUP-16 for diabetic foot ulcers. Core capabilities: Strain Engineering of Lactic-Acid Bacteria, Live-Biotherapeutic Process Development, Phase 1 Diabetic Foot Ulcer Program.
Editorial context
Related technical briefs
Briefs that name Kuopio as a covered market or city.